Products
Spevatamig Biosimilar Bispecific Antibody (CD47 × Claudin-18) for Research
Cat No.: GMP-Bios-INN-1399
Anti-IAP/CD47 therapeutic antibody (Pre-made Spevatamig biosimilar,Bispecific Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Spevatamig (development code PT-886) is a bispecific monoclonal antibody targeting CD47. It is developed by Phanes Therapeutics for Adenocarcinoma, Cancer, Pancreatic cancer in Phase I/II development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1399-1mg | 1mg | |
| GMP-Bios-INN-1399-10mg | 10mg | |
| GMP-Bios-INN-1399-100mg | 100mg | |
| GMP-Bios-INN-1399-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Spevatamig biosimilar, Bispecific Whole mAb, Anti-IAP/CD47;CLDN18 Antibody: Anti-CD47/Leukocyte surface antigen CD47/Antigenic surface determinant protein OA3/Integrin-associated protein (IAP) therapeutic antibody |
| INN Name | Spevatamig |
| Target | IAP/CD47;CLDN18 |
| Format | Bispecific Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G1;G1 |
| VD LC | Kappa;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I/II |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2024 |
| Year Recommended | na |
| Companies | Phanes Therapeutics |
| Conditions Approved | na |
| Conditions Active | Adenocarcinoma;Cancer;Pancreatic cancer |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
